Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4175 - Intracranial Activity of Ensartinib in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Targeted Therapy;  Supportive Care and Symptom Management

Tumour Site

Presenters

Heather Wakelee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

H. Wakelee1, K.L. Reckamp2, T.A. Leal3, S.P. Patel4, G. Blumenschein5, E. Shum6, J. Nieva7, G. Oxnard8, R.E. Sanborn9, S. Waqar10, K. Zeman11, G. Dukart12, K. Harrow13, C. Liang14, A. Holzhausen15, L. Horn16

Author affiliations

  • 1 Medicine/oncology, Stanford Advanced Medicine Center, 94305 - Stanford/US
  • 2 Associate Professor, City of Hope, 91010 - Duarte/US
  • 3 Medical Oncology, University of Wisconsin School of Medicine and Public Health, Madison/US
  • 4 Medicine, UC San Diego Moores Cancer Center, 92093 - La Jolla/US
  • 5 Thoracic/head And Neck Medical Oncology, MD Anderson Cancer Center, Houston/US
  • 6 Medical Oncology, New York University, New York/US
  • 7 Associate Professor Of Clinical Medicine, University of California, San Diego, San Diego/US
  • 8 Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 9 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland/US
  • 10 Assistant Professor, Washington University Medical School, St. Louis/US
  • 11 Medical Oncology, Walter Reed National Military Medical Center, Bathesda/US
  • 12 -, Xcovery Holdings, Inc., Palm Beach Gardens/US
  • 13 Vp, Clinical Operations, Xcovery Holding Company, LLC, 33405 - Palm Beach Gardens/US
  • 14 Cso, Xcovery Holdings, Inc., 33405 - Palm Beach Gardens/US
  • 15 Clinical Trial Manager, Xcovery Holdings, Inc., Palm Beach Gardens/US
  • 16 Associate Professor Of Medicine, Vanderbilt Ingram Cancer Center, 37232-6307 - Nashville/US
More

Resources

Abstract 4175

Background

Ensartinib is a potent ALK small molecule tyrosine kinase inhibitor (TKI). It has shown efficacy in intracranial tumor models. The activity of ensartinib is being evaluated in an ongoing phase 2 study of ALK positive NSCLC patients (pts). As progression due to growth of pre-existing brain metastases (BrM) or development of new BrM is a common mechanism of treatment resistance, we examined the clinical intracranial activity of ensartinib in pts with known BrM (target and/or non-target) at baseline or subsequent central nervous system (CNS) progression.

Methods

Pts who were either ALK TKI naïve (1st line), had received prior crizotinib and no other ALK TKI (2nd line), or had received prior crizotinib and a 2nd generation ALK TKI (3rd line) received ensartinib 225mg QD until disease progression (PD), unacceptable toxicity or investigator discretion. Tumor assessments were performed locally every 8 weeks. Pts with asymptomatic BrM at baseline were allowed to enroll. To be considered a CNS target lesion, it had to be > 3 mm in diameter and, if previously treated, must have been at least 4 weeks post whole brain radiation therapy with demonstrated tumor growth and may not have been treated by stereotactic radiosurgery.

Results

As of the data cut-off (May 1, 2018), 77 ALK evaluable pts (ALK+ NSCLC pts at > 200mg QD with a post baseline response assessment) were assessed. Overall, 23 pts (30%) had BrM progression (new or existing lesions). For 41 pts who had no BrM at baseline and received ensartinib as 1st line (10 pts), 2nd line (18 pts) or 3rd line (13 pts), only 2 pts (5%) progressed due to the development of BrM. For 36 pts who had BrM at baseline (5 as 1st line, 19 as 2nd line, 12 as 3rd line), 21 pts (58 %) had BrM progression, some at the time of systemic progression. For patients with baseline CNS target lesions, the CNS objective response rate was 100% (n = 3) for 1st line pts, 54% (n = 13) for 2nd line pts, and 33% (n = 3) for 3rd line pts; with a CNS disease control rate of 100% for all pts. Complete CNS responses were observed in 3 pts with target CNS lesions and in 3 pts with only non-target lesions.

Conclusions

The data indicate that ensartinib has promising CNS activity.

Clinical trial identification

NCT01625234.

Legal entity responsible for the study

Xcovery Holdings, Inc.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

H. Wakelee: Research support: Pfizer, Novartis, Xcovery. K.L. Reckamp: Research funds to institution: Xcovery; Consultant and research funds to institution: Ariad. T.A. Leal: Consultant: Takeda, AstraZeneca, Novartis, AbbVie, BMS. G. Blumenschein: Consultant: BMS, Bayer, Clovis, Merck, Celgene, AbbVie, Novartis; Research support: Xcovery, AstraZeneca. E. Shum: Consulting work: Boehringer Ingelheim. J. Nieva: Research support: Merck; Consultant: Genentech and AstraZeneca; Shareholder: Epic Sciences. G. Oxnard: Consulting: Takeda and Ignyta. R.E. Sanborn: Institutional support: Bristol‐Meyers Squibb and Medimmune; Research support: Merck (investigator‐initiated trial); Advisory boards: Peregrine Pharmaceuticals, Seattle Genetics; travel to research related meetings: Bristol‐Meyers Squibb, Five Prime Therapeutics. G. Dukart, K. Harrow, C. Liang, A. Holzhausen: Full time employee and stock options: Xcovery Holdings, Inc. L. Horn: Consulting: Xcovery Holding Company, BMS, BI, Abbvie, Genentech, Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.